• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Reports First Quarter 2026 Financial Results

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    • Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025
    • Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025
    • Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA
    • Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026.

    "I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins. Our growth outlook, combined with the progress made on value-creation initiatives and a strong start to the year, reinforces my confidence that we will deliver on our 2026 financial guidance," said Fred Lowery, Chief Executive Officer of Henry Schein. "I am committed to the Company's goal of achieving greater than $200 million of annual operating income improvement within the next few years, with a $125 million run-rate by the end of 2026. These initiatives, along with continued execution of our strategic plan, will contribute to us achieving high-single digit to low-double digit earnings growth in the coming years."

    "Over the last two months as I have immersed myself in the business and spoken with customers, suppliers and employees, it is clear that Henry Schein has great assets with a differentiated platform to serve as a trusted partner to healthcare practitioners worldwide. As we look ahead, I'm excited by the significant opportunities to accelerate growth through the use of technology, improve operational execution, and become a more agile company," added Mr. Lowery.

    First Quarter 2026 Financial Results

    • Total net sales for the quarter were $3.4 billion, an increase of 6.3% compared to the first quarter of 2025 and reflects 2.5% internal sales growth, 0.7% sales growth from acquisitions, and a 3.1% increase resulting from foreign currency exchange. First quarter sales growth is detailed in Exhibit A1.
    • Global Distribution and Value-Added Services sales for the quarter increased 6.1%, and reflects 2.5% internal sales growth, 0.6% sales growth from acquisitions, and a 3.0% increase resulting from foreign currency exchange compared with the first quarter of 2025. The main components are:
      • Global Dental Distribution merchandise sales for the quarter increased 9.0%, and by 3.0% internal sales growth, compared with the first quarter of 2025, with continuing strong momentum in the U.S.
      • Global Dental Distribution equipment sales for the quarter increased 8.6%, and by 3.5% internal sales growth, compared with the first quarter of 2025.
      • Global Medical Distribution sales for the quarter increased 1.7%, and by 1.3% internal sales growth, compared with the first quarter of 2025.
      • Global Value-Added Services sales for the quarter increased 10.6%, and by 7.8% internal sales growth, compared with the first quarter of 2025.
    • Global Specialty Products sales for the quarter increased 8.1%, and by 1.7% internal sales growth, 1.7% sales growth from acquisitions, and a 4.7% increase resulting from foreign currency exchange, compared with the first quarter of 2025.
    • Global Technology sales for the quarter increased 7.0%, and reflects 6.9% internal sales growth, 1.3% sales decrease due to a business disposal, and a 1.4% increase resulting from foreign currency exchange, compared with the first quarter of 2025.
    • GAAP net income2 for the quarter was $107 million, or $0.92 per diluted share4, and compares with first-quarter 2025 GAAP net income of $110 million, or $0.88 per diluted share.
    • Non-GAAP net income2 for the quarter was $153 million, or $1.32 per diluted share4, and compares with first-quarter 2025 non-GAAP net income of $143 million, or $1.15 per diluted share.
    • Adjusted EBITDA3 for the quarter was $289 million and compares with first-quarter 2025 Adjusted EBITDA of $259 million.
    • In the first quarter of 2026, the Company acquired a controlling interest in its S.I.N. distributor in the U.S. to enhance its position in the value implant market and support its business integration strategy. This transaction resulted in a remeasurement gain of $11 million.

    Share Repurchases

    During the first quarter of 2026, the Company repurchased approximately 1.6 million shares of common stock at an average price of $77.64 per share for a total of $125 million.

    At the end of the quarter, Henry Schein had $655 million authorized and available for future stock repurchases.

    2026 Financial Guidance

    Henry Schein today reaffirmed its financial guidance for 2026. Guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs, amortization expense of acquired intangible assets, the impairment of intangible assets, changes in contingent consideration, costs associated with shareholder advisory matters, select implementation-related costs supporting value creation initiatives, and litigation settlements. This guidance also assumes that foreign currency exchange rates remain generally consistent with current levels.

    • 2026 non-GAAP diluted EPS attributable to Henry Schein, Inc. is unchanged and expected to be $5.23 to $5.37.
    • 2026 total sales growth is unchanged and expected to be approximately 3% to 5% over 2025.
    • 2026 Adjusted EBITDA3 is unchanged and expected to grow mid-single digits compared with 2025.

    Adjustments to 2026 GAAP Net Income and Diluted EPS

    The Company is providing guidance for 2026 diluted EPS and for 2026 Adjusted EBITDA on a non-GAAP basis, as noted above. The Company is not providing a reconciliation of its 2026 non-GAAP diluted EPS guidance to its projected 2026 diluted EPS prepared on a GAAP basis, or its 2026 Adjusted EBITDA guidance to net income prepared on a GAAP basis. This is because the Company is unable to provide without unreasonable effort an estimate of restructuring expenses and related costs, including its ongoing value-creation initiatives, and the corresponding tax effect, which will be included in the Company's 2026 diluted EPS and net income, prepared on a GAAP basis. The inability to provide this reconciliation is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and timing of related costs.

    Management does not believe these items are representative of the Company's underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

    First-Quarter 2026 Conference Call Webcast

    The Company will hold a conference call to discuss first-quarter 2026 financial results today, beginning at 8:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein's website by visiting https://investor.henryschein.com/webcasts. In addition, a replay will be available beginning shortly after the call has ended for a period of one week.

    The Company will be posting slides that provide a summary of its first-quarter 2026 financial results on its website at https://investor.henryschein.com/financials/quarterly-results/.

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

    Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information

    In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

    These statements include total sales growth, EPS and Adjusted EBITDA guidance and are generally identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate," "to be," "to make", "have confidence or confident that it will" or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

    Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership (including, without limitation, the transition to a new Chief Executive Officer); our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; political, economic, and regulatory influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the wars in Ukraine and Iran, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports, including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

    We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

    Included within the press release are non-GAAP financial measures that supplement the Company's Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company's actual results prepared under GAAP to exclude certain items. In the schedule attached to the press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. The impact of certain items that are excluded include integration and restructuring costs, amortization of acquisition-related assets, the insurance claim recovery associated with the cybersecurity incident, changes in contingent consideration, costs associated with shareholder advisory matters and select value creation consulting costs, and litigation settlements because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate and occur on an unpredictable basis. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

    1 See Exhibit A for details of sales growth. Internal sales growth is calculated from total net sales using constant foreign currency exchange rates and excludes sales from acquisitions.

    2 See Exhibit B for a reconciliation of GAAP net income and diluted EPS to non-GAAP net income and diluted EPS.

    3 See Exhibit C for a reconciliation of GAAP net income to Adjusted EBITDA.

    4 References to diluted EPS refer to diluted EPS attributable to Henry Schein, Inc.

    (TABLES TO FOLLOW)

     

    HENRY SCHEIN, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (in millions, except share and per share data)

    (unaudited)

     

     

     

     

     

    Three Months Ended

     

     

     

     

     

    March 28,

     

    March 29,

     

     

     

     

     

    2026

     

    2025

     

     

     

     

     

     

     

     

     

     

    Net sales

     

    $

    3,368

     

    $

    3,168

    Cost of sales

     

     

    2,298

     

     

    2,168

     

     

    Gross profit

     

     

    1,070

     

     

    1,000

    Operating expenses:

     

     

     

     

     

     

     

    Selling, general and administrative

     

     

    809

     

     

    738

     

    Depreciation and amortization

     

     

    67

     

     

    62

     

    Restructuring and related costs

     

     

    12

     

     

    25

     

     

    Operating income

     

     

    182

     

     

    175

    Other income (expense):

     

     

     

     

     

     

     

    Interest income

     

     

    7

     

     

    6

     

    Interest expense

     

     

    (39)

     

     

    (35)

     

    Other, net

     

     

    -

     

     

    (1)

     

     

    Income before taxes, equity in earnings of affiliates and noncontrolling interests

     

     

    150

     

     

    145

    Income taxes

     

     

    (38)

     

     

    (35)

    Equity in earnings of affiliates, net of tax

     

     

    -

     

     

    3

    Net income

     

     

    112

     

     

    113

     

    Less: Net income attributable to noncontrolling interests

     

     

    (5)

     

     

    (3)

    Net income attributable to Henry Schein, Inc.

     

    $

    107

     

    $

    110

     

     

     

     

     

     

     

     

     

     

    Earnings per share attributable to Henry Schein, Inc.:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic

     

    $

    0.93

     

    $

    0.89

     

    Diluted

     

    $

    0.92

     

    $

    0.88

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

     

    114,939,640

     

     

    123,776,073

     

    Diluted

     

     

    116,061,244

     

     

    124,848,221

     

    HENRY SCHEIN, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in millions, except share data)

     

     

     

     

     

    March 28,

     

    December 27,

     

     

     

     

     

    2026

     

    2025

     

     

     

     

     

    (unaudited)

     

     

    ASSETS

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    138

     

    $

    156

     

    Accounts receivable, net of allowance for credit losses of $96 and $90

     

     

    1,719

     

     

    1,651

     

    Inventories, net

     

     

    2,014

     

     

    2,002

     

    Prepaid expenses and other

     

     

    625

     

     

    655

     

     

     

    Total current assets

     

     

    4,496

     

     

    4,464

    Property and equipment, net

     

     

    618

     

     

    621

    Operating lease right-of-use assets

     

     

    312

     

     

    301

    Goodwill

     

     

    4,284

     

     

    4,213

    Other intangibles, net

     

     

    1,007

     

     

    1,018

    Investments and other

     

     

    587

     

     

    598

     

     

     

    Total assets

     

    $

    11,304

     

    $

    11,215

     

     

     

     

     

     

     

     

     

     

    LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

     

    Accounts payable

     

    $

    1,043

     

    $

    1,154

     

    Bank credit lines

     

     

    1,046

     

     

    764

     

    Current maturities of long-term debt

     

     

    35

     

     

    33

     

    Operating lease liabilities

     

     

    78

     

     

    78

     

    Accrued expenses:

     

     

     

     

     

     

     

     

    Payroll and related

     

     

    262

     

     

    340

     

     

    Taxes

     

     

    192

     

     

    179

     

     

    Other

     

     

    641

     

     

    680

     

     

     

    Total current liabilities

     

     

    3,297

     

     

    3,228

    Long-term debt

     

     

    2,327

     

     

    2,310

    Deferred income taxes

     

     

    158

     

     

    146

    Operating lease liabilities

     

     

    263

     

     

    251

    Other liabilities

     

     

    437

     

     

    486

     

     

     

    Total liabilities

     

     

    6,482

     

     

    6,421

     

     

     

     

     

     

     

     

     

     

    Redeemable noncontrolling interests

     

     

    903

     

     

    895

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

     

    Preferred stock, $0.01 par value, 1,000,000 shares authorized,

     

     

     

     

     

     

     

     

    none outstanding

     

     

    -

     

     

    -

     

    Common stock, $0.01 par value, 480,000,000 shares authorized,

     

     

     

     

     

     

     

     

    114,424,682 issued and outstanding on March 28, 2026 and

     

     

     

     

     

     

     

     

    115,771,149 issued and outstanding on December 27, 2025

     

     

    1

     

     

    1

     

    Additional paid-in capital

     

     

    167

     

     

    177

     

    Retained earnings

     

     

    3,287

     

     

    3,293

     

    Accumulated other comprehensive loss

     

     

    (189)

     

     

    (226)

     

     

    Total Henry Schein, Inc. stockholders' equity

     

     

    3,266

     

     

    3,245

     

    Noncontrolling interests

     

     

    653

     

     

    654

     

     

     

    Total stockholders' equity

     

     

    3,919

     

     

    3,899

     

     

    Total liabilities, redeemable noncontrolling interests and stockholders' equity

     

    $

    11,304

     

    $

    11,215

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    HENRY SCHEIN, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in millions)/(unaudited)

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

     

     

    March 28,

     

    March 29,

     

     

     

     

     

     

    2026

     

    2025

     

     

     

     

     

     

     

     

     

     

     

    Cash flows from operating activities:

     

     

     

     

     

     

     

    Net income

     

    $

    112

     

    $

    113

     

    Adjustments to reconcile net income to net cash provided by (used in) operating activities:

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    81

     

     

    73

     

     

     

    Impairment charge on intangible assets

     

     

    -

     

     

    1

     

     

     

    Non-cash restructuring and related charges

     

     

    2

     

     

    1

     

     

     

    Stock-based compensation expense

     

     

    3

     

     

    5

     

     

     

    Provision for losses on trade and other accounts receivable

     

     

    6

     

     

    2

     

     

     

    Provision for (benefit from) deferred income taxes

     

     

    2

     

     

    (7)

     

     

     

    Equity in earnings of affiliates

     

     

    -

     

     

    (3)

     

     

     

    Distributions from equity affiliates

     

     

    3

     

     

    2

     

     

     

    Changes in unrecognized tax benefits

     

     

    (1)

     

     

    2

     

     

     

    Other

     

     

    (27)

     

     

    (27)

     

     

     

    Changes in operating assets and liabilities, net of acquisitions:

     

     

     

     

     

     

     

     

     

     

    Accounts receivable

     

     

    (69)

     

     

    (74)

     

     

     

     

    Inventories

     

     

    8

     

     

    (14)

     

     

     

     

    Other current assets

     

     

    6

     

     

    75

     

     

     

     

    Accounts payable and accrued expenses

     

     

    (223)

     

     

    (112)

    Net cash provided by (used in) operating activities

     

     

    (97)

     

     

    37

     

     

     

     

     

     

     

     

     

     

     

    Cash flows from investing activities:

     

     

     

     

     

     

     

    Purchases of property and equipment

     

     

    (25)

     

     

    (31)

     

    Payments related to equity investments and business acquisitions,

     

     

     

     

     

     

     

     

    net of cash acquired

     

     

    (24)

     

     

    (51)

     

    Proceeds from loan to affiliate

     

     

    1

     

     

    -

     

    Capitalized software costs

     

     

    (14)

     

     

    (12)

     

    Other

     

     

    (1)

     

     

    (5)

    Net cash used in investing activities

     

     

    (63)

     

     

    (99)

     

     

     

     

     

     

     

     

     

     

     

    Cash flows from financing activities:

     

     

     

     

     

     

     

    Net change in bank credit lines

     

     

    283

     

     

    215

     

    Proceeds from issuance of long-term debt

     

     

    57

     

     

    150

     

    Principal payments for long-term debt

     

     

    (39)

     

     

    (15)

     

    Proceeds from issuance of stock upon exercise of stock options

     

     

    1

     

     

    1

     

    Payments for repurchases and retirement of common stock

     

     

    (125)

     

     

    (161)

     

    Payments for taxes related to shares withheld for employee taxes

     

     

    (9)

     

     

    (12)

     

    Distributions to noncontrolling shareholders

     

     

    (16)

     

     

    (4)

     

    Payments for contingent consideration

     

     

    -

     

     

    (12)

     

    Acquisitions of noncontrolling interests in subsidiaries

     

     

    (32)

     

     

    (73)

    Net cash provided by financing activities

     

     

    120

     

     

    89

     

     

     

     

     

     

     

     

     

     

     

    Effect of exchange rate changes on cash and cash equivalents

     

     

    22

     

     

    (22)

     

     

     

     

     

     

     

     

     

     

     

    Net change in cash and cash equivalents

     

     

    (18)

     

     

    5

    Cash and cash equivalents, beginning of period

     

     

    156

     

     

    122

    Cash and cash equivalents, end of period

     

    $

    138

     

    $

    127

    Exhibit A - First Quarter Sales

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Henry Schein, Inc.

    2026 First Quarter

    Sales Summary

    (in millions)

    (unaudited)

    Q1 2026 over Q1 2025

     

    Constant Currency

     

     

     

     

     

     

     

    Growth

     

     

     

     

     

     

    Q1 2026

     

    Q1 2025

     

    Local Internal Growth

     

    Acquisition Growth

     

    Total Constant Currency Growth

     

    Foreign Exchange Impact

     

    Total Sales Growth

    U.S. Distribution and Value-Added Services

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Merchandise

    $

    624

     

    $

    591

     

    4.1%

     

    1.5%

     

    5.6%

     

    0.0%

     

    5.6%

    Equipment

     

    194

     

     

    187

     

    3.4%

     

    0.0%

     

    3.4%

     

    0.0%

     

    3.4%

    Value-Added Services

     

    48

     

     

    45

     

    6.2%

     

    0.0%

     

    6.2%

     

    0.0%

     

    6.2%

    Total Dental

     

    866

     

     

    823

     

    4.1%

     

    1.0%

     

    5.1%

     

    0.0%

     

    5.1%

    Medical

     

    1,043

     

     

    1,030

     

    1.2%

     

    0.1%

     

    1.3%

     

    0.0%

     

    1.3%

    Total U.S. Distribution and Value-Added Services

     

    1,909

     

     

    1,853

     

    2.5%

     

    0.5%

     

    3.0%

     

    0.0%

     

    3.0%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    International Distribution and Value-Added Services

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Merchandise

     

    668

     

     

    594

     

    1.8%

     

    1.1%

     

    2.9%

     

    9.6%

     

    12.5%

    Equipment

     

    223

     

     

    197

     

    3.6%

     

    0.0%

     

    3.6%

     

    9.8%

     

    13.4%

    Value-Added Services

     

    9

     

     

    7

     

    18.9%

     

    9.5%

     

    28.4%

     

    12.6%

     

    41.0%

    Total Dental

     

    900

     

     

    798

     

    2.4%

     

    0.8%

     

    3.2%

     

    9.8%

     

    13.0%

    Medical

     

    30

     

     

    25

     

    4.7%

     

    0.0%

     

    4.7%

     

    11.4%

     

    16.1%

    Total International Distribution and Value-Added Services

     

    930

     

     

    823

     

    2.5%

     

    0.8%

     

    3.3%

     

    9.8%

     

    13.1%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Global Distribution and Value-Added Services

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Global Merchandise

     

    1,292

     

     

    1,185

     

    3.0%

     

    1.2%

     

    4.2%

     

    4.8%

     

    9.0%

    Global Equipment

     

    417

     

     

    384

     

    3.5%

     

    0.0%

     

    3.5%

     

    5.1%

     

    8.6%

    Global Value-Added Services

     

    57

     

     

    52

     

    7.8%

     

    1.2%

     

    9.0%

     

    1.6%

     

    10.6%

    Global Dental

     

    1,766

     

     

    1,621

     

    3.2%

     

    1.0%

     

    4.2%

     

    4.8%

     

    9.0%

    Global Medical

     

    1,073

     

     

    1,055

     

    1.3%

     

    0.1%

     

    1.4%

     

    0.3%

     

    1.7%

    Total Global Distribution and Value-Added Services

     

    2,839

     

     

    2,676

     

    2.5%

     

    0.6%

     

    3.1%

     

    3.0%

     

    6.1%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Global Specialty Products

     

    397

     

     

    367

     

    1.7%

     

    1.7%

     

    3.4%

     

    4.7%

     

    8.1%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Global Technology

     

    173

     

     

    162

     

    6.9%

     

    -1.3%

     

    5.6%

     

    1.4%

     

    7.0%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliminations

     

    (41)

     

     

    (37)

     

    n/a

     

    n/a

     

    n/a

     

    n/a

     

    n/a

    Total Global

    $

    3,368

     

    $

    3,168

     

    2.5%

     

    0.7%

     

    3.2%

     

    3.1%

     

    6.3%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Exhibit B

     

     

     

     

     

     

     

     

     

    Henry Schein, Inc.

    2026 First Quarter

    Reconciliation of reported GAAP net income and diluted EPS attributable to Henry Schein, Inc.

    to non-GAAP net income and diluted EPS attributable to Henry Schein, Inc.

    (in millions, except per share data)

    (unaudited)

     

     

     

     

     

     

     

     

     

     

     

    First Quarter

     

     

     

     

     

     

     

     

    %

     

     

     

    2026

     

     

    2025

     

    Growth

     

    Net income attributable to Henry Schein, Inc.

    $

    107

     

    $

    110

     

    (2.3)

    %

    Diluted EPS attributable to Henry Schein, Inc.

    $

    0.92

     

    $

    0.88

     

    4.5

    %

     

     

     

     

     

     

     

     

     

    Non-GAAP Adjustments, net of tax and attribution to noncontrolling interests

     

     

     

     

     

     

     

     

    Restructuring and related costs (1)

    $

    8

     

    $

    17

     

     

     

    Acquisition intangible amortization (2)

     

    27

     

     

    27

     

     

     

    Cyber incident-insurance proceeds, net of third-party advisory expenses (3)

     

    -

     

     

    (15)

     

     

     

    Change in contingent consideration (4)

     

    1

     

     

    (2)

     

     

     

    Costs associated with shareholder advisory matters and select implementation related value creation consulting costs (5)

     

    10

     

     

    6

     

     

     

    Non-GAAP adjustments to net income

    $

    46

     

    $

    33

     

     

     

     

     

     

     

     

     

     

     

     

    Non-GAAP adjustments to diluted EPS

    $

    0.39

     

    $

    0.27

     

     

     

     

     

     

     

     

     

     

     

     

    Non-GAAP net income attributable to Henry Schein, Inc.

    $

    153

     

    $

    143

     

    6.5

    %

    Non-GAAP diluted EPS attributable to Henry Schein, Inc.

    $

    1.32

     

    $

    1.15

     

    14.8

    %

    Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Net income growth rates are based on actual values and may not recalculate due to rounding. Amounts may not sum due to rounding.

    (1)

     

    Restructuring and Related Costs

     

     

     

     

     

     

     

     

     

     

     

     

    The following table presents details of our restructuring and related costs:

     

     

     

     

     

     

     

     

     

     

     

    First Quarter

     

     

     

    2026

     

    2025

     

     

    Restructuring and related costs - pre-tax, as reported

    $

    12

     

    $

    25

     

     

    Income tax benefit

     

    (3)

     

     

    (7)

     

     

    Amount attributable to noncontrolling interests

     

    (1)

     

     

    (1)

     

     

    Restructuring and related costs, net

    $

    8

     

    $

    17

    (2)

     

    Acquisition Intangible Amortization

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    The following table presents details of amortization of acquired intangible assets:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    First Quarter

     

     

     

    2026

     

    2025

     

     

    Acquisition intangible amortization - pre-tax, as reported

    $

    45

     

    $

    43

     

     

    Income tax benefit

     

    (11)

     

     

    (10)

     

     

    Amount attributable to noncontrolling interests

     

    (7)

     

     

    (6)

     

     

    Acquisition intangible amortization, net

    $

    27

     

    $

    27

    (3)

     

    Represents cyber insurance proceeds, net of one time professional and other fees related to remediation of our Q4 2023 cyber incident. During Q1 2025, we received insurance proceeds of $20 million ($15 million, net of taxes) under this policy representing the remaining insurance recovery of losses related to the cyber incident.

     

     

     

    (4)

     

    Represents a change in the fair value of contingent consideration of $1 million ($1 million, net of taxes) and ($2) million (($2) million, net of taxes) recorded during Q1 2026 and Q1 2025, respectively, related to certain 2023 and 2025 acquisitions.

     

     

     

    (5)

     

    Represents costs associated with shareholder advisory matters and select implementation related value creation consulting costs of $13 million ($10 million, net of taxes) and $8 million ($6 million, net of taxes) recorded during Q1 2026 and Q1 2025, respectively.

     

     

     

     

     

     

    Exhibit C

     

     

     

     

     

     

    Henry Schein, Inc.

    2026 First Quarter

    Reconciliation of reported GAAP net income to Adjusted EBITDA

    (in millions)

    (unaudited)

     

     

     

     

     

     

     

    First Quarter

     

     

    2026

     

     

    2025

    Net income attributable to Henry Schein, Inc. (GAAP)

    $

    107

     

    $

    110

    Income attributable to noncontrolling interests

     

    5

     

     

    3

    Net income (GAAP)

     

    112

     

     

    113

    Definitional adjustments:

     

     

     

     

     

    Interest income

     

    (7)

     

     

    (6)

    Interest expense

     

    39

     

     

    35

    Income taxes

     

    38

     

     

    35

    Depreciation and amortization

     

    81

     

     

    73

    Non-GAAP adjustments:

     

     

     

     

     

    Restructuring and related costs

     

    12

     

     

    25

    Cyber incident-insurance proceeds, net of third-party advisory expenses

     

    -

     

     

    (20)

    Impairment of intangible assets

     

    -

     

     

    1

    Change in contingent consideration

     

    1

     

     

    (2)

    Costs associated with shareholder advisory matters and select implementation related value creation consulting costs

     

    13

     

     

    8

    Other adjustments:

     

     

     

     

     

    Equity in earnings of affiliates, net of tax

     

    -

     

     

    (3)

    Adjusted EBITDA (non-GAAP)

    $

    289

     

    $

    259

     

     

     

     

     

     

    Adjusted EBITDA is a non-GAAP measure that we calculate in the manner reflected on Exhibit C. We define Adjusted EBITDA as net income, excluding (i) net income attributable to noncontrolling interests, (ii) interest income and expense, (iii) income taxes, (iv) depreciation and amortization, (v) restructuring and related costs, (vi) cyber incident-insurance proceeds, net of third-party advisory expenses, (vii) impairment of intangible assets, (viii) change in contingent consideration, (ix) costs associated with shareholder advisory matters and select implementation related value creation consulting costs, and (x) equity in earnings of affiliates, net of tax. Amounts may not sum due to rounding.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260504754689/en/

    Investors



    Ronald N. South

    Senior Vice President and Chief Financial Officer

    ronald.south@henryschein.com

    (631) 843-5500



    Graham Stanley

    Vice President, Investor Relations and Strategic Financial Project Officer

    graham.stanley@henryschein.com

    (631) 843-5500



    Media



    Tim Vassilakos

    Vice President, Global Corporate Communications

    timothy.vassilakos@henryschein.com

    (516) 510-0926

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    4/16/2026Neutral
    BTIG Research
    4/15/2026$100.00Buy
    Citigroup
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14

    5/22/26 8:00:00 AM ET
    $DHR
    $HSIC
    $NVST
    Industrial Machinery/Components
    Industrials
    Medical Specialities
    Health Care

    Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

    Top performers achieve 75% case acceptance vs. 45% industry average, signaling that clinical consistency, not scale alone, drives predictable growth and enterprise value Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution. Across both DSOs and independent practices, the highest-perf

    5/14/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Murphy Kelly Ann claimed ownership of 34,812 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/28/26 5:01:47 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: Former Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4/A - HENRY SCHEIN INC (0001000228) (Issuer)

    5/26/26 5:16:26 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/22/26 7:03:42 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Henry Schein

    BTIG Research initiated coverage of Henry Schein with a rating of Neutral

    4/16/26 8:03:48 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Henry Schein with a new price target

    Citigroup initiated coverage of Henry Schein with a rating of Buy and set a new price target of $100.00

    4/15/26 8:08:55 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $691,900 worth of shares (10,000 units at $69.19) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/12/26 4:15:46 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form SD filed by Henry Schein Inc.

    SD - HENRY SCHEIN INC (0001000228) (Filer)

    5/29/26 3:04:28 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    5/22/26 8:00:11 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Henry Schein Inc.

    DEFA14A - HENRY SCHEIN INC (0001000228) (Filer)

    5/12/26 9:00:08 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2026 financial results before the stock market opens on Tuesday, May 5, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Frederick M. Lowery, Chief Executive Officer and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Schein website following the prese

    4/21/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care